Question 1

What is Ilunocitinib?

Accepted Answer

Ilunocitinib is a Other.

Question 2

How often does Ilunocitinib appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 251 articles.

Question 3

When was Ilunocitinib first tracked by Ergen?

Accepted Answer

First tracked on May 18, 2026.

Question 4

When was Ilunocitinib last mentioned in news?

Accepted Answer

Last active on Jun 10, 2026.

Question 5

What is Ilunocitinib's current news sentiment?

Accepted Answer

Aggregate sentiment score: 30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Ilunocitinib in global news coverage?

Accepted Answer

Attention score of 7, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Ilunocitinib?

Accepted Answer

Zoetis Securities Fraud Class Actions (May 18, 2026, 251 articles).

Question 8

How did the "Zoetis Securities Fraud Class Actions" event impact Ilunocitinib?

Accepted Answer

Ilunocitinib is an Elanco product marketed as comparable or superior to Zoetis' Oclacitinib and Lokivetmab at a lower price point, leading to market share losses for Zoetis.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.